Guidance Uncertainty Resolved At Albany Molecular Research, 2015 Margin Expansion Now In Focus

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating and $19.00 price target on

. In the report, Morgan Stanley noted, "With uncertainty about 2015 guidance now resolved, investor focus should now shift to execution in 2015, with key value drivers being potential for margin expansion in thecore business and executing on M&A strategy." Albany Molecular Research closed on Thursday at $17.22.